

Please amend the claims as follows:

7. (Amended) The method of claim 1, wherein the immune response reduces or inhibits [inhibit] growth of the pathogen.

24. (Twice amended) A pharmaceutical composition comprising a tumor [an] antigen RNA and a [an] pharmaceutical carrier, which pharmaceutical carrier is suitable for *in vivo* delivery to a human.

Respectfully submitted,



Raina Semionow  
Reg. No. 39,022  
Attorney for Applicants

DARBY & DARBY, P.C.  
Post Office Box 5257  
New York, N.Y. 10150-5257  
Phone (212) 527-7700

::ODMA\WORLD\OX\IM:\2650\1F966US2\RXS1180.WPD